Name Type of Trial Main Intervention Control Main Findings
population
studied
FDPS Diabetes Pre – diabetic Lifestyle Usual care
Prevention Middle age
DPP Diabetes Pre – diabetic Lifestyle or Placebo Metformin reduced incidence of developing TDM.
Prevention Middle age Metformin Lifestyle > metformin
STOP- Diabetes Pre – diabetic Acarbose Placebo
NIDDM Prevention Middle age
XENDOS Diabetes Pre – diabetic Orlistat Placebo GI ADR >91%
Prevention Middle age
DREAM Diabetes Pre – diabetic Rosiglitazone Placebo NNT 7.5 over 3 years
Prevention Middle age
CANOE Diabetes Pre – diabetic Rosiglitazone Placebo
Prevention Middle age + Metformin
ACT-NOW Diabetes Pre – diabetic Pioglitazone Placebo
Prevention Middle age
DCCT Glucose T1DM MDI insulin or 1-2 Insulin Intensive BG control reduced micro and macro and all
(F/U Study Control Trial Late 20s CSII Inj per day cause mortality (50-60%)
EDIC) (3 or more) 50% reduction in microvascular complications over 6 years with
intensive glycemic lowering regime
Reduction in albuminuria (DCCT/EDIC)
Reduced LT risk of impaired GFR (EDIC)
UKPDS 33 Glucose T2DM (new) SU’s or Insulin Diet CVD neutral but decreased over LT f/u
Control Trial & Middle age (Intensive) Reduced micro
Drug Control Insulin decreased A1C significantly
Trial (Insulin) Weight gain + risk of hypo
UKPDS 34 Glucose T2DM (new Metformin Diet CVD neutral but decreased over LT 10 yr
Control diagnosis) (intensive) f/u (macro benefit)
Middle age Reduced micro
population
studied
FDPS Diabetes Pre – diabetic Lifestyle Usual care
Prevention Middle age
DPP Diabetes Pre – diabetic Lifestyle or Placebo Metformin reduced incidence of developing TDM.
Prevention Middle age Metformin Lifestyle > metformin
STOP- Diabetes Pre – diabetic Acarbose Placebo
NIDDM Prevention Middle age
XENDOS Diabetes Pre – diabetic Orlistat Placebo GI ADR >91%
Prevention Middle age
DREAM Diabetes Pre – diabetic Rosiglitazone Placebo NNT 7.5 over 3 years
Prevention Middle age
CANOE Diabetes Pre – diabetic Rosiglitazone Placebo
Prevention Middle age + Metformin
ACT-NOW Diabetes Pre – diabetic Pioglitazone Placebo
Prevention Middle age
DCCT Glucose T1DM MDI insulin or 1-2 Insulin Intensive BG control reduced micro and macro and all
(F/U Study Control Trial Late 20s CSII Inj per day cause mortality (50-60%)
EDIC) (3 or more) 50% reduction in microvascular complications over 6 years with
intensive glycemic lowering regime
Reduction in albuminuria (DCCT/EDIC)
Reduced LT risk of impaired GFR (EDIC)
UKPDS 33 Glucose T2DM (new) SU’s or Insulin Diet CVD neutral but decreased over LT f/u
Control Trial & Middle age (Intensive) Reduced micro
Drug Control Insulin decreased A1C significantly
Trial (Insulin) Weight gain + risk of hypo
UKPDS 34 Glucose T2DM (new Metformin Diet CVD neutral but decreased over LT 10 yr
Control diagnosis) (intensive) f/u (macro benefit)
Middle age Reduced micro
